Tags: NASH
Recent Research and Insights on the Disease Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
G&H How has the prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis changed? ZY The prevalence of both nonalcoholic fatty liver disease (NAFLD) and nonalcoholic […]
Emerging Research on MGL-3196 for the Treatment of Nonalcoholic Steatohepatitis
G&H What is the mechanism of action of MGL-3196? ZY MGL-3196 (Madrigal Pharmaceuticals) is a thyroid hormone receptor β agonist. Thyroid hormone receptors can be […]
Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States and is the leading cause of chronic liver disease […]
Pharmacologic Management of Nonalcoholic Steatohepatitis
Abstract: Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a major form of chronic liver disease in adults and children. Although improved dietary habits and regular […]
Overview of Current and Emerging Therapeutic Approaches to Nonalcoholic Steatohepatitis
G&H What role do diet and exercise play in the treatment of nonalcoholic steatohepatitis? SH Diet and exercise are the cornerstone of therapy for patients […]
Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis
G&H How common are nonalcoholic steatohepatitis and hepatocellular carcinoma in the United States, and how often do they coexist in a patient? MC Fatty liver […]
Diagnosis of Nonalcoholic Steatohepatitis Without Liver Biopsy
G&H What is the relationship between nonalcoholic steatohepatitis and nonalcoholic fatty liver disease, and how common are these conditions? BM Nonalcoholic fatty liver disease (NAFLD) […]
Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials
Abstract: Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise […]